Physician profile
Kandee Hammill
NPI 1720706823
$2,089.44
in general payments reported to CMS, 2019-2025
13 companies · $1,510 in 2025
The $1,510 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $118 · 2023: $79.46 · 2024: $382 · 2025: $1,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,706 · Education: $216 · Honoraria: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,705.68 |
| Education | $215.98 |
| Honoraria | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $487.10 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $325.04 | 2025 | Uzedy, Austedo Xr |
| Indivior INC. | $287.44 | 2024-2025 | Sublocade |
| Abbvie INC. | $272.64 | 2022-2025 | |
| Braeburn INC. | $191.41 | 2024-2025 | Brixadi |
| Neurocrine Biosciences, INC. | $173.71 | 2024-2025 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $84.09 | 2022-2023 | |
| Gilead Sciences, INC. | $78.52 | 2024-2025 | Epclusa |
| Otsuka America Pharmaceutical, INC. | $65.70 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| H2-Pharma, LLC | $50.00 | 2025 | |
| Sanofi Pasteur INC. | $30.26 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.33 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $17.20 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kandee Hammill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.